MedTrace Logo

The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus

NCT04091854 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2021-08-26

No results posted yet for this study

Summary

At present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of GKA hypoglycemic drug. This study intends to observe the clinical remission rate of diabetes mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes mellitus who have been treated with HMS5552 for 52W or 28W and whose glucose control is up to the standard.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

HMS5552

To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus

Sponsors & Collaborators

  • Majianhua

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04091854 on ClinicalTrials.gov